This technical reference provides an in-depth breakdown of the CJC-1295 Drug Affinity Complex (DAC) molecular architecture, GHRH receptor binding kinetics, and laboratory reconstitution metrics. Designed for bioanalytical researchers, this guide outlines exact physical structures, covalent albumin conjugation pathways, and precise solvent calculations for in vitro assays.
This technical reference provides an in-depth breakdown of the CJC-1295 Drug Affinity Complex (DAC) molecular architecture, GHRH receptor binding kinetics, and laboratory reconstitution metrics. Designed for bioanalytical researchers, this guide outlines exact physical structures, covalent albumin conjugation pathways, and precise solvent calculations for in vitro assays.
A "drug affinity complex" CJC-1295 diagram illustrates how a modified 29-amino-acid growth hormone-releasing hormone (GHRH) analog covalently binds to circulating serum albumin via a reactive maleimide linker attached to a lysine residue at the C-terminus. This irreversible albumin conjugation protects the peptide chain from rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and neutral renal clearance, extending its active elimination half-life from minutes to several days in animal models.
In preclinical structural models, the Drug Affinity Complex (DAC) moiety consists of a reactive N-maleimidopropionyl group fused to the C-terminal Lys30 residue of the modified GHRH(1-29) sequence. When introduced into aqueous matrix assays or laboratory plasma samples, the maleimide electrophile selectively reacts with the nucleophilic thiol group of Cys34 on endogenous serum albumin. The resulting stable thioether bond forms a macromolecular conjugate that maintains receptor-binding affinity while significantly altering pharmacokinetic parameters.
To evaluate GHRH signaling in laboratory settings, researchers must distinguish between modified GRF 1-29 (often labeled as CJC-1295 No DAC) and true CJC-1295 DAC. The base peptide consists of D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These structural modifications improve resistance to enzymatic cleavage compared to native GHRH, but without the DAC linker, the half-life remains relatively short (approximately 30 minutes in rodent models).
When studying the extended-release capabilities of CJC-1295 DAC, the addition of the maleimidopropionyl-lysine complex changes the molecular weight from approximately 3,367 Da to over 67,000 Da once conjugated with albumin. This structural enlargement restricts glomerular filtration in renal tissue, allowing sustained activation of the GHRH receptor (GHRHR) on pituitary somatotropes. Laboratories investigating chronic growth hormone secretion patterns select CJC-1295 DAC when constant receptor stimulation is required without repetitive dosing schedules.
Calculating the correct solvent volume for lyophilized peptide vials is essential for maintaining accurate pipetting concentrations during automated assays. When preparing a standard 2 mg or 5 mg vial of CJC-1295 DAC combined with Ipamorelin, laboratories routinely utilize high-purity bacteriostatic water containing 0.9% benzyl alcohol to prevent microbial growth during multi-use experimental protocols.
For a standard 5 mg total peptide lyophilized cake (e.g., 2 mg CJC-1295 + 3 mg Ipamorelin), adding 2.5 mL of sterile bacteriostatic water yields a final concentration of 2 mg/mL total peptide stock (0.8 mg/mL CJC-1295 and 1.2 mg/mL Ipamorelin). Adding 1.0 mL of reconstituting diluent creates a concentrated 5 mg/mL solution, whereas 5.0 mL provides a 1 mg/mL solution suited for micro-volume microplate readers. Maintaining standardized volumetric diluents ensures reproducible serial dilutions across complex in vitro experiments.
Analytical rigor is fundamental to consistent research outcome reproduction. Lower-grade raw materials often contain truncated peptide impurities, residual trifluoroacetic acid (TFA), or bacterial endotoxins that interfere with cell culture viability and receptor binding assays. PX1 Research enforces stringent verification protocols on every batch.
The table below highlights the critical analytical metrics required for high-precision GHRH and secretagogue research:
In preclinical endocrinology studies, co-administering a GHRH analog with a Growth Hormone Secretagogue Receptor (GHSR) agonist produces a synergistic amplification of growth hormone pulse amplitude. While CJC-1295 acts directly upon the GHRH receptor to activate adenylate cyclase and increase intracellular cyclic AMP (cAMP), compounds like Ipamorelin target the ghrelin/GHSR-1a pathway, triggering intracellular calcium release via phospholipase C.
In vitro pituitary cell cultures demonstrate that simultaneous activation of both distinct intracellular signaling cascades yields a non-linear, multiplicative increase in GH transcription and secretion compared to activating either pathway independently. Researchers exploring systemic somatotropic signaling often cross-reference data from our comprehensive research library hub to design optimized multi-target receptor assays.
When selecting GHRH class peptides for comparative receptor kinetics, laboratories evaluate half-life, structural modification, and binding affinity profiles. Sermorelin represents the unmodified 29-amino-acid N-terminal segment of endogenous GHRH, exhibiting rapid clearance and short-duration pituitary stimulation ideal for pulsatile baseline models.
Conversely, Tesamorelin incorporates a trans-3-hexenoic acid group attached to the N-terminal Tyr1 residue, enhancing enzymatic stability specifically for lipid metabolism and hepatic gene expression studies. While Tesamorelin and Sermorelin require frequent reconstitution handling due to shorter decay curves, CJC-1295 DAC remains unique in its ability to covalently bind serum albumin, sustaining elevate downstream IGF-1 transcription over prolonged incubation periods. For complete assay planning, explore our full catalog of research peptides.
Proper reconstitution of lyophilized peptides is vital to avoid mechanical shear stress and denaturing of the secondary peptide structure. Diluent should be directed down the glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirling or inversion should be employed; vortexing must be strictly avoided as hydrophobic interactions can cause aggregation or precipitation.
Once reconstituted with bacteriostatic water, CJC-1295 solutions should be stored at 2°C to 8°C (36°F to 46°F) and used within 28 days to prevent hydrolysis or thermal decay. Unreconstituted lyophilized vials should be preserved at -20°C for long-term storage up to 24 months. Laboratories requiring bulk quantities for longitudinal studies can set up custom supply schedules via our wholesale lab accounts portal.
Quantifying the biological activity of CJC-1295 DAC in preclinical research typically relies on enzyme-linked immunosorbent assays (ELISA) or quantitative real-time PCR (qPCR) measuring downstream hepatic expression of insulin-like growth factor 1 (IGF-1). Because GHRH stimulation induces transcription of IGF-1 and IGF-binding protein 3 (IGFBP-3), measuring serum or supernatant concentrations of these proteins provides a robust proxy for GHRH receptor activation.
Researchers analyzing somatotropic signaling pathways can reference detailed research models in our guide on growth hormone secretagogue mechanisms. Combining GHRH analogs with selective GHRP compounds, such as GHRP-6, allows investigation into how dual receptor occupancy alters expression of metabolic pathways, nitrogen retention markers, and cellular repair proteins.
What does a "drug affinity complex" CJC-1295 diagram illustrate?
A CJC-1295 Drug Affinity Complex (DAC) diagram shows the covalent conjugation between the reactive maleimidopropionyl group on the peptide's C-terminus and the Cys34 thiol residue of endogenous serum albumin. This bond protects the peptide from rapid enzymatic degradation by DPP-IV and renal filtration.
How much bacteriostatic water should be added to a CJC-1295 Ipamorelin blend?
For a standard 5 mg total peptide vial (e.g., 2 mg CJC-1295 + 3 mg Ipamorelin), adding 2.5 mL of bacteriostatic water yields a clear concentration of 2 mg/mL total peptide. Adding 1.0 mL produces a 5 mg/mL solution, while 5.0 mL produces a 1 mg/mL solution.
What is the primary role of CJC-1295 in laboratory research?
CJC-1295 acts as a GHRH analog. Preclinical studies evaluate CJC-1295 as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair and metabolic research.
How does CJC-1295 DAC differ from CJC-1295 No DAC (Modified GRF 1-29)?
CJC-1295 DAC includes a maleimide-containing linker that covalently binds to circulating serum albumin, extending its clearance half-life to several days in animal models. Modified GRF 1-29 lacks this affinity complex and exhibits a half-life of approximately 30 minutes.
What purity verification standards does PX1 Research provide for CJC-1295?
PX1 Research provides lot-specific, third-party Certificates of Analysis (COA) containing RP-HPLC purity reports (≥98%), mass spectrometry identity verification, and kinetic chromogenic LAL endotoxin testing (<0.01 EU/mg).
How should reconstituted CJC-1295 be stored in the laboratory?
Reconstituted CJC-1295 solutions prepared with bacteriostatic water should be stored refrigerated at 2°C to 8°C and protected from light. Under these conditions, the solution maintains stability for up to 28 days.
What receptor pathways do CJC-1295 and Ipamorelin target?
CJC-1295 binds to the growth hormone-releasing hormone receptor (GHRHR) to increase intracellular cAMP, whereas Ipamorelin targets the growth hormone secretagogue receptor (GHSR-1a) to induce calcium influx.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based GMP-compliant facilities and shipped directly from distribution centers in California and Arizona with same-day dispatch for orders placed Monday through Friday.
Can CJC-1295 DAC be vortexed during reconstitution?
No. Lyophilized peptides should never be vortexed during reconstitution. Rapid mechanical agitation can disrupt hydrophobic tertiary structures and lead to peptide aggregation. Gentle swirling is recommended.
What alternative GHRH analogs can be compared with CJC-1295?
Sermorelin (GRF 1-29) and Tesamorelin are frequently studied alongside CJC-1295 to evaluate variations in receptor degradation rates, structural N-terminal modifications, and downstream hepatic IGF-1 expression.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.